One point of interest will be how the treatments are priced.
We already from JCR that the Japanese heath system will pay well in advance of the cost of a painkiller for a course of treatment in the aGVHD space.
Equally life threatening, probably more so, is what happens down the track to those people who survive long enough to get an LVAD and do not get a heart transplant.
It is about avoiding the ongoing cost to health systems and to peoples lives.
Future Company Valuations in general & MSB, page-5
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |